Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taub, J. W.
Right arrow Articles by Matherly, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taub, J. W.
Right arrow Articles by Matherly, L. H.
[Cancer Research 60, 6421-6426, November 15, 2000]
© 2000 American Association for Cancer Research


Immunology

Cystathionine-ß-Synthase cDNA Transfection Alters the Sensitivity and Metabolism of 1-ß-D-Arabinofuranosylcytosine in CCRF-CEM Leukemia Cells in Vitro and in Vivo: A Model of Leukemia in Down Syndrome1

Jeffrey W. Taub2, Xi Huang, Yubin Ge, Julie A. Dutcher, Mark L. Stout, Ramzi M. Mohammad, Yaddanapudi Ravindranath and Larry H. Matherly

Division of Pediatric Hematology/Oncology, Children’s Hospital of Michigan [J. W. T., M. L. S., Y. R.], Experimental and Clinical Therapeutics Program, Barbara Ann Karmanos Cancer Institute [J. W. T., X. H., Y. G. R. M. M., Y. R., L. H. M.], and Departments of Pediatrics [J. W. T., Y. R.], Pharmacology [L. H. M.], and Internal Medicine [J. A. D., R. M. M.], Wayne State University School of Medicine, Detroit, Michigan 48201

The significantly higher event-free survival rates of Down syndrome (DS) children with acute myeloid leukemia compared with non-DS children is linked to increased sensitivity of DS myeloblasts to 1-ß-D-arabinofuranosylcytosine (ara-C) and the enhanced metabolism of ara-C to ara-C triphosphate (J. W. Taub et al., Blood, 87: 3395–3403, 1996). The cystathionine-ß-synthase (CBS) gene (localized to chromosome 21q22.3) may have downstream effects on reduced folate and S-adenosylmethionine pathways; ara-C metabolism and folate pools are linked by the known synergistic effect of sequential methotrexate and ara-C therapy. We have shown that relative CBS transcripts were significantly higher in DS compared with non-DS myeloblasts, and CBS transcript levels correlated with in vitro ara-C sensitivity (J. W. Taub et al., Blood, 94: 1393–1400, 1999). A leukemia cell line model to study the relationship of the CBS gene and ara-C metabolism/sensitivity was developed by transfecting CBS-null CCRF-CEM cells with the CBS cDNA. CBS-transfected cells were a median 15-fold more sensitive in vitro to ara-C compared with wild-type cells and generated 8.5-fold higher [3H]ara-C triphosphate levels after in vitro incubation with [3H]ara-C. Severe combined immunodeficient mice implanted with CBS-transfected CEM cells demonstrated greater responsiveness to therapy, reflected in significantly prolonged survivals after ara-C administration compared with mice implanted with wild-type cells and treated with the same dosage schedule. The transfected cells also demonstrated increased in vitro and in vivo sensitivity to gemcitabine. Deoxycytidine kinase (dCK) activity was approximately 22-fold higher in transfected CEM cells compared with wild-type cells. However, levels of dCK transcripts on Northern blots and protein levels on Western blots were nearly identical between CBS-transfected and wild-type cells. Collectively, these results suggest a posttranscriptional regulation of dCK in CBS-overexpressing cells that contributes to increased ara-C phosphorylation and drug activity. Further elucidating the mechanisms of increased sensitivity of DS cells to ara-C related to the CBS gene may lead to the application of these novel approaches to acute myeloid leukemia therapy for non-DS patients.




This article has been cited by other articles:


Home page
JCOHome page
K. Kudo, S. Kojima, K. Tabuchi, H. Yabe, A. Tawa, M. Imaizumi, R. Hanada, K. Hamamoto, R. Kobayashi, A. Morimoto, et al.
Prospective Study of a Pirarubicin, Intermediate-Dose Cytarabine, and Etoposide Regimen in Children With Down Syndrome and Acute Myeloid Leukemia: The Japanese Childhood AML Cooperative Study Group
J. Clin. Oncol., December 1, 2007; 25(34): 5442 - 5447.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
U. Sen, N. Tyagi, M. Kumar, K. S. Moshal, W. E. Rodriguez, and S. C. Tyagi
Cystathionine- -synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells
Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1779 - C1787.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. V. Massey, A. Zipursky, M. N. Chang, J. J. Doyle, S. Nasim, J. W. Taub, Y. Ravindranath, G. Dahl, and H. J. Weinstein
A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481
Blood, June 15, 2006; 107(12): 4606 - 4613.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
Y. Ge, M. L. Stout, D. A. Tatman, T. L. Jensen, S. Buck, R. L. Thomas, Y. Ravindranath, L. H. Matherly, and J. W. Taub
GATA1, Cytidine Deaminase, and the High Cure Rate of Down Syndrome Children With Acute Megakaryocytic Leukemia
J Natl Cancer Inst, February 2, 2005; 97(3): 226 - 231.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Ge, T. L. Jensen, M. L. Stout, R. M. Flatley, P. J. Grohar, Y. Ravindranath, L. H. Matherly, and J. W. Taub
The Role of Cytidine Deaminase and GATA1 Mutations in the Increased Cytosine Arabinoside Sensitivity of Down Syndrome Myeloblasts and Leukemia Cell Lines
Cancer Res., January 15, 2004; 64(2): 728 - 735.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
D. E. Hansel, A. Rahman, M. Hidalgo, P. J. Thuluvath, K. D. Lillemoe, R. Shulick, J.-L. Ku, J.-G. Park, K. Miyazaki, R. Ashfaq, et al.
Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression Technology
Am. J. Pathol., July 1, 2003; 163(1): 217 - 229.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Ge, T. L. Jensen, L. H. Matherly, and J. W. Taub
Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines
Blood, February 15, 2003; 101(4): 1551 - 1557.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. M. Zwaan, G. J. L. Kaspers, R. Pieters, K. Hahlen, G. E. Janka-Schaub, C. H. van Zantwijk, D. R. Huismans, E. de Vries, M. G. Rots, G. J. Peters, et al.
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome
Blood, January 1, 2002; 99(1): 245 - 251.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Ge, L. H. Matherly, and J. W. Taub
Transcriptional Regulation of Cell-specific Expression of the Human Cystathionine beta -Synthase Gene by Differential Binding of Sp1/Sp3 to the -1b Promoter
J. Biol. Chem., November 16, 2001; 276(47): 43570 - 43579.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2000 by the American Association for Cancer Research.